1. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
   Xuewen Liu et al, 2017, Oncol Rep CrossRef
2. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A
   Qiuyue Huang et al, 2017 CrossRef
3. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: Involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway
   Shijie Cao et al, 2016 CrossRef
4. Single molecule force spectroscopy for in-situ probing oridonin inhibited ROS-mediated EGF-EGFR interactions in living KYSE-150 cells
   Jiang Pi et al, 2017, Pharmacological Research CrossRef
5. Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer
   Xiaoning Yuan et al, 2017 CrossRef
6. Interleukin-3 stimulates matrix metalloproteinase 12 production from macrophages promoting thoracic aortic aneurysm/dissection
   Chang Liu et al, 2018, Clin. Sci. CrossRef
7. Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by in Silico and in Vitro Analyses
   Onat Kadioglu et al, 2018, Front. Pharmacol. CrossRef
8. Oridonin enhances the cytotoxicity of 5-FU in renal carcinoma cells by inducting necroptotic death
   Wei Zheng et al, 2018, Biomedicine & Pharmacotherapy CrossRef
9. Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M
   Yuwei Wang et al, 2018, Front. Pharmacol. CrossRef
10. Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis
    Yunfei Zhang et al, 2018, Journal of Pharmacological Sciences CrossRef
11. Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway
    Ning Wang et al, 2018, Life Sciences CrossRef
12. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Pengfei Liu et al, 2019, Molecules CrossRef
13. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia
    Wenjing Ma et al, 2019, Journal of Pharmacological Sciences CrossRef
14. ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent apoptosis in human colorectal cancer cells
    Di Zhang et al, 2019, Biochemical and Biophysical Research Communications CrossRef
15. Overexpression of CIP2A is associated with poor prognosis in multiple myeloma
    Xuewen Liu et al, 2017, Sig Transduct Target Ther CrossRef
16. Oridonin elevates sensitivity of ovarian carcinoma cells to cisplatin via suppressing cisplatin-mediated autophagy
    Yaxian Zhao et al, 2019, Life Sciences CrossRef
17. Matrix metalloproteinases: their functional role in lung cancer.
    Neha Merchant et al, 2017, Carcinogenesis CrossRef
18. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)
    null Rangasamy et al, 2019, Molecules CrossRef
19. The prognostic impact of traditional Chinese medicine monomers on tumor-associated macrophages in non-small cell lung cancer
    Liang-Qin WAN et al, 2019, Chinese Journal of Natural Medicines CrossRef
20. Polyphyllin I activates AMPK to suppress the growth of non-small-cell lung cancer via induction of autophagy
    Yezi Wu et al, 2020, Archives of Biochemistry and Biophysics CrossRef
21. Vasohibin 1 inhibits Adriamycin resistance in osteosarcoma cells via the protein kinase B signaling pathway
    Wei Huang et al, 2018, Oncol Lett CrossRef
22. Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer
    Xuewen Liu et al, 2018, Int J Oncol CrossRef
23. LPS aggravates lung inflammation induced by RSV by promoting the ERK-MMP-12 signaling pathway in mice
    Shenglin Chen et al, 2020, Respir Res CrossRef
24. An Insight into the Anti-Angiogenic and Anti-Metastatic Effects of Oridonin: Current Knowledge and Future Potential
    Nurul Akmaryanti Abdullah et al, 2021, Molecules CrossRef
25. Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
    Hisham Saafan et al, 2021, Cells CrossRef
26. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity.
    Xiang Li et al, 2021, Front Pharmacol CrossRef
27. Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways.
    Xianping Che et al, 2021, Biomed Res Int CrossRef
28. Blocking MMP-12-modulated epithelial-mesenchymal transition by repurposing penfluridol restrains lung adenocarcinoma metastasis via uPA/uPAR/TGF-β/Akt pathway
    Wen-Yueh Hung et al, 2021, Cell Oncol. CrossRef
29. Recent progress of oridonin and its derivatives for cancer therapy and drug resistance
    Yong-Feng Guan et al, 2021, Med Chem Res CrossRef
30. Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)
    Hiu Lee et al, 2021, Oncol Lett CrossRef
31. Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review.
    Zhicheng Wei et al, 2023, J Ethnopharmacol CrossRef
32. Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
    Xiaotong Song et al, 2023, Front. Pharmacol. CrossRef
33. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance
    Xi Liu et al, 2021, Genes & Diseases CrossRef
34. Exploring the mechanism by which quercetin re-sensitizes breast cancer to paclitaxel: network pharmacology, molecular docking, and experimental verification
    Ye Yang et al, 2023, Naunyn-Schmiedeberg's Arch Pharmacol CrossRef
35. Oridonin inhibits the occurrence and development of colorectal cancer by reversing the Warburg effect via reducing PKM2 dimer formation and preventing its entry into the nucleus
    Fan Chen et al, 2023, European Journal of Pharmacology CrossRef
36. Exploring the composition of protein-ligand binding sites for cancerous inhibitor of PP2A (CIP2A) by inhibitor guided binding analysis: paving a new way for the Discovery of drug candidates against triple negative breast cancer (TNBC)
    Oluwayimika Ibitoye et al, 2024, Journal of Receptors and Signal Transduction CrossRef
37. The Natural Product Oridonin as an Anticancer Agent: Current Achievements and Problems
    Xiangyan Hu et al, 2024, CPB CrossRef
38. Oridonin ameliorates renal fibrosis in diabetic nephropathy by inhibiting the Wnt/β-catenin signaling pathway
    Jushuang Li et al, 2024, Renal Failure CrossRef
39. Serving up health: How phytochemicals transform food into medicine in the battle against cancer
    Eshita Sharma et al, 2024, Food Frontiers CrossRef
40. Network Pharmacology and in vitro Experimental Verification on Intervention of Oridonin on Non-Small Cell Lung Cancer
    Ke Chang et al, 2024, Chin. J. Integr. Med. CrossRef
41. H2S-releasing oridonin derivatives with improved antitumor activity by inhibiting the PI3K/AKT pathway
    Haonan Li et al, 2024, Bioorganic & Medicinal Chemistry CrossRef
42. Matrix metalloproteinases, chemoresistance and cancer
    Khadijeh Jamialahmadi et al, 2025 CrossRef